| Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-01 17:01:00 |
Czytaj oryginał (ang.) |
| GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline |
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern. |
zacks.com |
2025-05-01 16:35:42 |
Czytaj oryginał (ang.) |
| Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript |
Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Allen Gong - J.P. Morgan David Saxon - Needham Adam Maeder - Piper Sandler Joanne Wuensch - Citibank Margaret Andrew - William Blair Richard Newitter - Truist Securities Michael Sarcone - Jefferies Anthony Petrone - Mizzou Group Danielle Antalffy - UBS Patrick Wood - Morgan Stanley Operator Welcome to Glaukos Corporation First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-01 02:05:59 |
Czytaj oryginał (ang.) |
| Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates |
Glaukos (GKOS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.70 per share a year ago. |
zacks.com |
2025-04-30 22:30:47 |
Czytaj oryginał (ang.) |
| Glaukos Announces First Quarter 2025 Financial Results |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net. |
businesswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Baron Health Care Fund Q1 2025 Top Contributors And Detractors |
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts. |
seekingalpha.com |
2025-04-29 15:30:00 |
Czytaj oryginał (ang.) |
| Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-23 15:06:14 |
Czytaj oryginał (ang.) |
| Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 25-28, 2025 in Los Angeles, CA. Glaukos will be exhibiting onsite at booth #2227. |
businesswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Glaukos Announces the Release of its 2024 Sustainability Report |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2024 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company's website here. “I am prou. |
businesswire.com |
2025-04-16 11:00:00 |
Czytaj oryginał (ang.) |
| Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025. A link to th. |
businesswire.com |
2025-04-09 11:00:00 |
Czytaj oryginał (ang.) |
| 3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space |
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy. |
zacks.com |
2025-03-31 14:10:34 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain Glaukos Stock in Your Portfolio |
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. |
zacks.com |
2025-03-13 08:58:18 |
Czytaj oryginał (ang.) |
| GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock? |
Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year increase. This growth was driven by strong demand for its innovative glaucoma and corneal health solutions. |
zacks.com |
2025-02-28 12:46:35 |
Czytaj oryginał (ang.) |
| FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery |
On Monday, Glaukos Corporation GKOS received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review. |
benzinga.com |
2025-02-24 11:12:46 |
Czytaj oryginał (ang.) |
| Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment. |
businesswire.com |
2025-02-24 09:00:00 |
Czytaj oryginał (ang.) |
| GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline |
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern. |
zacks.com |
2025-02-21 11:40:30 |
Czytaj oryginał (ang.) |
| Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript |
Glaukos Corporation (NYSE:GKOS ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President, Investor Relations and Corporate Affairs Tom Burns - Chairman and Chief Executive Officer Joe Gilliam - President and Chief Operating Officer Conference Call Participants Tom Stephen - Stifel Richard Newitter - Truist Securities Allen Gong - JPMorgan Michael Sarcone - Jefferies Mason Carrico - Stephens Anthony Petrone - Mizuho Danielle Antalffy - UBS Operator Welcome to Glaukos Corporation's Fourth Quarter and Full-Year 2024 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today are available at www.glaukos.com. |
seekingalpha.com |
2025-02-21 06:29:11 |
Czytaj oryginał (ang.) |
| Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates |
Glaukos (GKOS) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.63 per share a year ago. |
zacks.com |
2025-02-20 20:40:23 |
Czytaj oryginał (ang.) |
| What to Expect From These 3 MedTech Stocks This Earnings Season? |
Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow. |
zacks.com |
2025-02-19 10:21:10 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings |
Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-17 12:21:10 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain Glaukos Stock in Your Portfolio Now |
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. |
zacks.com |
2025-02-07 16:46:15 |
Czytaj oryginał (ang.) |
| Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 20. |
businesswire.com |
2025-01-23 09:00:00 |
Czytaj oryginał (ang.) |
| GKOS Stock Gains Following Positive Study Data on iDose Platform |
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX. |
zacks.com |
2025-01-15 11:55:25 |
Czytaj oryginał (ang.) |
| Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform, including: In a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials, iDose TR (travoprost intracameral implant) 75 mcg, an FDA-. |
businesswire.com |
2025-01-14 18:05:00 |
Czytaj oryginał (ang.) |
| Here's Why You Should Add Glaukos Stock to Your Portfolio Now |
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. |
zacks.com |
2025-01-09 10:56:21 |
Czytaj oryginał (ang.) |
| Glaukos Reaches 52-Week High: What's Driving the Stock's Rally? |
Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets. |
zacks.com |
2025-01-07 14:57:20 |
Czytaj oryginał (ang.) |
| Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday |
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. |
benzinga.com |
2024-12-31 10:59:29 |
Czytaj oryginał (ang.) |
| Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA |
GKOS announces New Drug Application submission for its Epioxa to the FDA. |
zacks.com |
2024-12-24 15:41:11 |
Czytaj oryginał (ang.) |
| Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal dise. |
businesswire.com |
2024-12-23 09:00:00 |
Czytaj oryginał (ang.) |
| Glaukos: Still Bullish, But Embedded Expectations Are Now High |
Glaukos Corporation (GKOS) is well-positioned to grow sales at a CAGR of ~20% to FY'27, potentially hitting $680mm in revenues and $90-$100mm post-tax earnings. The stock is currently valued at 21x sales, with high expectations for future growth, but a 27% margin of safety exists at current prices. GKOS's efficient asset base and strong cash conversion support sustainable growth, driven by iDose TR and iStent infinite uptake in domestic and international markets. |
seekingalpha.com |
2024-12-21 09:04:19 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen |
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog. |
zacks.com |
2024-12-12 05:16:11 |
Czytaj oryginał (ang.) |
| Here's Why You Should Add Glaukos Stock to Your Portfolio Now |
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. |
zacks.com |
2024-12-11 11:36:08 |
Czytaj oryginał (ang.) |
| 5 Medical Device Stocks That Survived the 2024 Market Volatility |
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025. |
zacks.com |
2024-12-11 10:55:37 |
Czytaj oryginał (ang.) |
| Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos |
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong. |
benzinga.com |
2024-12-02 16:29:58 |
Czytaj oryginał (ang.) |
| Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally? |
GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks. |
zacks.com |
2024-11-21 11:50:37 |
Czytaj oryginał (ang.) |
| Glaukos Announces Participation in Upcoming Investor Conferences |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40 p.m. ET in New York City, NY Stephens Annual Investment Conference on Wednesday, Novembe. |
businesswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-05 14:31:08 |
Czytaj oryginał (ang.) |
| Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds |
Glaukos Corp GKOS reported on Monday third-quarter sales of $96.7 million, up 24% year-over-year, beating the consensus of $91.49 million. |
benzinga.com |
2024-11-05 14:21:19 |
Czytaj oryginał (ang.) |
| GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates |
Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern. |
zacks.com |
2024-11-05 13:01:45 |
Czytaj oryginał (ang.) |
| Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript |
Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Lawrence Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Allen Gong - JPMorgan David Saxon - Needham Michael Sarcone - Jefferies Joanne Wuensch - Citigroup Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Welcome to Glaukos Corporation's Third Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-11-05 01:03:05 |
Czytaj oryginał (ang.) |
| Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates |
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago. |
zacks.com |
2024-11-04 20:31:21 |
Czytaj oryginał (ang.) |
| Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-28 13:05:36 |
Czytaj oryginał (ang.) |
| GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa |
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa. |
zacks.com |
2024-10-17 16:15:45 |
Czytaj oryginał (ang.) |
| Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held October 18-21, 2024, in Chicago, IL. Glaukos will be exhibiting onsite at booth #2608. In addition, Glauko. |
businesswire.com |
2024-10-14 11:00:00 |
Czytaj oryginał (ang.) |
| Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 |
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 4, 2024. A link to t. |
businesswire.com |
2024-10-09 11:00:00 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain Glaukos Stock in Your Portfolio Now |
GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism. |
zacks.com |
2024-10-08 19:20:19 |
Czytaj oryginał (ang.) |